{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:52:14Z","timestamp":1792047134763,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1136\/ard-2023-224185","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T17:20:10Z","timestamp":1690219210000},"page":"1387-1393","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":66,"title":["Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study"],"prefix":"10.1016","volume":"82","author":[{"given":"Ho","family":"So","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsz On","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2147-0995","authenticated-orcid":false,"given":"Steven Ho Man","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6410-8852","authenticated-orcid":false,"given":"Lai-Shan","family":"Tam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ard-2023-224185_bib1","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1161\/01.CIR.0000054612.26458.B2","article-title":"Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis","volume":"107","author":"Solomon","year":"2003","journal-title":"Circulation"},{"key":"10.1136\/ard-2023-224185_bib2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.15420\/ecr.2020.44","article-title":"Atherosclerotic cardiovascular disease in rheumatoid arthritis: impact of inflammation and Antirheumatic treatment","volume":"16","author":"Kerola","year":"2021","journal-title":"Eur Cardiol"},{"key":"10.1136\/ard-2023-224185_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12016-018-8714-z","article-title":"Atherosclerosis in rheumatoid arthritis: promoters and opponents","volume":"58","author":"Carbone","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1136\/ard-2023-224185_bib4","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1136\/ard.2005.038638","article-title":"Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data","volume":"65","author":"Da Silva","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib5","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jbspin.2010.02.040","article-title":"Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review","volume":"78","author":"Ruyssen-Witrand","year":"2011","journal-title":"Joint Bone Spine"},{"key":"10.1136\/ard-2023-224185_bib6","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1093\/rheumatology\/kem311","article-title":"Long-term exposure to medium-dose glucocorticoid therapy Associates with hypertension in patients with rheumatoid arthritis","volume":"47","author":"Panoulas","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"10.1136\/ard-2023-224185_bib7","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/annrheumdis-2016-eular.4403","article-title":"Ab0271\u2005effects of glucocorticoids on endothelial function: focus on rheumatoid arthritis","volume":"75","author":"Verhoeven","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib8","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/bmj.316.7134.811","article-title":"Meta-analysis of short-term low dose prednisolone versus placebo and non-Steroidal anti-inflammatory drugs in rheumatoid arthritis","volume":"316","author":"Gotzsche","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard-2023-224185_bib9","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1136\/bmj.316.7134.789","article-title":"Corticosteroids in rheumatoid arthritis","volume":"316","author":"Dennison","year":"1998","journal-title":"BMJ"},{"key":"10.1136\/ard-2023-224185_bib10","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/ard.2006.069252","article-title":"QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries","volume":"66","author":"Sokka","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib11","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1136\/rmdopen-2017-000536","article-title":"Glucocorticoids in rheumatoid arthritis: Current status and future studies","volume":"6","author":"Hua","year":"2020","journal-title":"RMD Open"},{"key":"10.1136\/ard-2023-224185_bib12","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"American college of rheumatology guideline for the treatment of rheumatoid arthritis","volume":"73","author":"Fraenkel","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1136\/ard-2023-224185_bib13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying Antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib14","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1136\/ard-2022-223365","article-title":"Efficacy of synthetic and biological Dmards: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis","volume":"82","author":"Kerschbaumer","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib15","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2021-220577","article-title":"Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis","volume":"80","author":"Ocon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib16","doi-asserted-by":"crossref","first-page":"100441","DOI":"10.1016\/j.jhepr.2022.100441","article-title":"Novel machine learning models outperform risk scores in predicting hepatocellular carcinoma in patients with chronic viral hepatitis","volume":"4","author":"Wong","year":"2022","journal-title":"JHEP Rep"},{"key":"10.1136\/ard-2023-224185_bib17","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.3233\/JAD-215312","article-title":"Demographics and medication use of patients with late-onset Alzheimer's disease in Hong Kong","volume":"87","author":"Wong","year":"2022","journal-title":"J Alzheimers Dis"},{"key":"10.1136\/ard-2023-224185_bib18","doi-asserted-by":"crossref","first-page":"3388","DOI":"10.1002\/sim.5753","article-title":"A Tutorial on propensity score estimation for multiple treatments using generalized boosted models","volume":"32","author":"McCaffrey","year":"2013","journal-title":"Stat Med"},{"key":"10.1136\/ard-2023-224185_bib19","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1524-4733.2009.00671.x","article-title":"Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals","volume":"13","author":"Xu","year":"2010","journal-title":"Value Health"},{"key":"10.1136\/ard-2023-224185_bib20","first-page":"kead039","article-title":"Five-year cardiovascular event risk in early rheumatoid arthritis patients who received treat-to-target management: a case-control study","author":"On","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1136\/ard-2023-224185_bib21","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s13075-017-1461-3","article-title":"Factors associated with oral glucocorticoid use in patients with rheumatoid arthritis: a drug use study from a prospective national Biologics Registry","volume":"19","author":"Black","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224185_bib22","doi-asserted-by":"crossref","first-page":"e87965","DOI":"10.1371\/journal.pone.0087965","article-title":"Confounding by indication probably distorts the relationship between steroid use and cardiovascular disease in rheumatoid arthritis: results from a prospective cohort study","volume":"9","author":"van Sijl","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/ard-2023-224185_bib23","doi-asserted-by":"crossref","first-page":"R30","DOI":"10.1186\/ar2383","article-title":"Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study","volume":"10","author":"Naranjo","year":"2008","journal-title":"Arthritis Res Ther"},{"key":"10.1136\/ard-2023-224185_bib24","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/eji.1830201112","article-title":"Glucocorticoids inhibit the production of Il6 from monocytes, endothelial cells and fibroblasts","volume":"20","author":"Waage","year":"1990","journal-title":"Eur J Immunol"},{"key":"10.1136\/ard-2023-224185_bib25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/PL00012387","article-title":"Targets of glucocorticoid action on TNF-alpha release by Macrophages","volume":"50","author":"Joyce","year":"2001","journal-title":"Inflamm Res"},{"key":"10.1136\/ard-2023-224185_bib26","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.thromres.2011.03.025","article-title":"The nuclear factor-Kappa B pathway in Atherosclerosis: a potential therapeutic target for Atherothrombotic vascular disease","volume":"128","author":"Pamukcu","year":"2011","journal-title":"Thromb Res"},{"key":"10.1136\/ard-2023-224185_bib27","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/ar300","article-title":"NF-Kappa B in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction","volume":"3","author":"Makarov","year":"2001","journal-title":"Arthritis Res"},{"issue":"Pt 12","key":"10.1136\/ard-2023-224185_bib28","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1242\/jcs.00461","article-title":"NF-kappaB signalling is inhibited by glucocorticoid receptor and Stat6 via distinct mechanisms","volume":"116","author":"Nelson","year":"2003","journal-title":"J Cell Sci"},{"key":"10.1136\/ard-2023-224185_bib29","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1210\/er.2002-0006","article-title":"The interplay between the glucocorticoid receptor and nuclear factor-kappaB or activator Protein-1: molecular mechanisms for gene repression","volume":"24","author":"De Bosscher","year":"2003","journal-title":"Endocr Rev"},{"key":"10.1136\/ard-2023-224185_bib30","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/art.38210","article-title":"Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis","volume":"66","author":"del Rinc\u00f3n","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/ard-2023-224185_bib31","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/ard.2010.129916","article-title":"Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis","volume":"70","author":"Greenberg","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib32","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1136\/annrheumdis-2021-221957","article-title":"Low dose, add-on prednisolone in patients with rheumatoid arthritis aged 65+: the pragmatic randomised, double-blind placebo-controlled GLORIA trial","volume":"81","author":"Boers","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib33","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1136\/annrheumdis-2011-201067","article-title":"Low-dose prednisone Chronotherapy for rheumatoid arthritis: a randomised clinical trial (CAPRA-2)","volume":"72","author":"Buttgereit","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0140-6736(20)30636-X","article-title":"Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, Multicentre, randomised controlled trial","volume":"396","author":"Burmester","year":"2020","journal-title":"Lancet"},{"key":"10.1136\/ard-2023-224185_bib35","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1136\/ard.2008.095539","article-title":"Efficacy of prednisone 1-4 mg\/day in patients with rheumatoid arthritis: a randomised, double-blind, placebo controlled withdrawal clinical trial","volume":"68","author":"Pincus","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib36","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/art.21204","article-title":"Baseline levels of C-reactive protein and prediction of death from cardiovascular disease in patients with inflammatory Polyarthritis: a ten-year followup study of a primary care-based inception cohort","volume":"52","author":"Goodson","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1136\/ard-2023-224185_bib37","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1136\/ard-2023-224185_bib38","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1136\/annrheumdis-2015-208916","article-title":"Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force","volume":"75","author":"Strehl","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/ard-2023-224185_bib39","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/annrheumdis-2022-222339","article-title":"Optimising both disease control and glucocorticoid dosing is essential for bone protection in patients with rheumatic disease","volume":"81","author":"Wiebe","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724102658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724102658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ard-2023-224185","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:29:16Z","timestamp":1749806956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724102658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":39,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0003496724102658"],"URL":"https:\/\/doi.org\/10.1136\/ard-2023-224185","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ard-2023-224185","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 \u00a9 Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}